Tetanus and Botulism in the ICU — Comprehensive Management · ICU Topics

Overview

ICU contrast of tetanus rigidity and spasms versus botulism descending flaccid paralysis with ventilatory support, clinical-blue educational scene — FigureTetanus and botulism are clostridial toxin opposites — tetanus causes uncontrolled excitation and rigidity; botulism causes descending flaccid paralysis. Both need early antitoxin/immunoglobulin and prolonged ICU care.

The one-paragraph exam answer

TETANUS = Clostridium tetani exotoxin (tetanospasmin) blocks inhibitory neurotransmitters (GABA, glycine) in spinal cord → sustained muscle contraction (TRISMUS, RISUS SARDONICUS, OPISTHOTONOS) + autonomic instability. Management: HTIG 500 IU IM (neutralise circulating toxin) + metronidazole (eradicate C. tetani) + benzodiazepines (diazepam/midazolam — control spasms by enhancing residual GABA) + magnesium sulfate (2-4 g/hr infusion — controls spasms AND autonomic instability by blocking calcium channels at NMJ and presynaptic neurons) + ICU (dark quiet room, minimal handling, airway/ventilation, autonomic monitoring) + wound debridement + vaccination (tetanus toxoid — infection does NOT confer immunity — must vaccinate to prevent recurrence). BOTULISM = Clostridium botulinum toxin blocks acetylcholine release at NMJ (cleaves SNARE proteins) → DESCENDING FLACCID PARALYSIS (ptosis/diplopia → dysphagia/dysarthria → respiratory failure) + dilated pupils + dry mouth + normal sensation + normal consciousness. Forms: foodborne (home-canned), wound (IV drug use), infant (honey). Management: botulinum antitoxin (equine heptavalent — for foodborne/wound — does NOT reverse existing paralysis but prevents progression) + supportive ventilation (prolonged — weeks-months — NMJ recovery requires new axonal terminals) + wound debridement (for wound botulism) ± penicillin/metronidazole (wound botulism only — NOT for foodborne). Mortality: tetanus 10-40%, botulism 5-10%.[1][2]

Tetanus and botulism — the key contrast

Tetanus vs botulism — neurotoxin-mediated opposites

Feature	Tetanus	Botulism
Organism	Clostridium tetani	Clostridium botulinum
Toxin	Tetanospasmin	Botulinum toxin (A, B, E most common)
Toxin action	Blocks INHIBITORY neurotransmitters (GABA, glycine) in spinal cord → UNCONTROLLED EXCITATION	Blocks ACETYLCHOLINE release at NMJ → PARALYSIS (pre-synaptic blockade)
Clinical pattern	SUSTAINED MUSCLE CONTRACTION (spasms, rigidity) — TOO MUCH tone	FLACCID PARALYSIS — NO tone (too little)
Direction of spread	ASCENDING (from wound site → trunk → head)	DESCENDING (cranial nerves → respiratory → limbs)
Classic features	Trismus (lockjaw), risus sardonicus (sardonic smile), opisthotonos (arched back)	Ptosis, diplopia, dysphagia, dysarthria, dilated pupils, dry mouth, descending paralysis
Autonomic	AUTONOMIC INSTABILITY (labile BP/HR, sweating)	Anticholinergic features (dry mouth, constipation, urinary retention, dilated pupils)
Consciousness	PRESERVED (patient is awake during spasms — terrifying)	PRESERVED (patient is awake but paralysed — 'locked-in')
Sensation	PRESERVED	PRESERVED (sensory neurons unaffected)
ICU management	Dark quiet room, benzodiazepines, magnesium, airway, autonomic control	Ventilation (prolonged), antitoxin, airway, supportive
Antidote	HTIG (human tetanus immunoglobulin) — neutralises circulating toxin	Botulinum antitoxin (equine) — neutralises circulating toxin
Recovery time	2-6 weeks (new synapse formation)	Weeks-months (new axonal terminal formation at NMJ)
Mortality	10-40% (higher in developing countries, elderly)	5-10% (respiratory failure)

[1]

Pathophysiology — how two clostridial toxins produce opposite syndromes

Tetanospasmin blocks GABA/glycine release in spinal cord; botulinum toxin cleaves SNARE proteins blocking acetylcholine release at NMJ — FigureTetanospasmin blocks inhibitory neurotransmission (GABA/glycine) → spasms; botulinum toxin blocks ACh release at the NMJ → flaccid paralysis.

Tetanus and botulism are the perfect examination pair precisely because their toxins are STRUCTURALLY HOMOLOGOUS (both 150 kDa zinc-endopeptidase A–B toxins, both target SNARE proteins) yet their CLINICAL effects are mirror images. The difference is entirely in WHERE the toxin acts: tetanospasmin acts in the SPINAL CORD on INHIBITORY neurons, while botulinum toxin acts at the PERIPHERAL cholinergic synapse on EXCITATORY (acetylcholine) release. [1]

Tetanus — tetanospasmin and loss of presynaptic inhibition

Tetanus pathophysiology — step by step

INOCULATION: Clostridium tetani (Gram-positive, spore-forming, obligately anaerobic bacillus) spores enter through a break in the skin. The wound is often MINOR and may have HEALED by presentation — splinter, insect bite, IV injection site, chronic ulcer, postpartum/abortion, umbilical stump (neonatal tetanus). Spores germinate ONLY in anaerobic, necrotic, low-redox tissue.
TOXIN PRODUCTION: Germinating bacilli release tetanospasmin (teTx), a 150 kDa zinc-endopeptidase A–B toxin synthesised as a single polypeptide and proteolytically nicked into a heavy chain (binding + translocation, 100 kDa) and a light chain (catalytic zinc-endopeptidase, 50 kDa) joined by a disulphide bond.
UPTAKE AT THE NEUROMUSCULAR JUNCTION: The heavy chain binds GD1b/GT1b gangliosides and the Niemann-Pick C1 (NPC1) receptor on the PRESYNAPTIC membrane of the ALPHA MOTOR NEURON at the NMJ. TeTx enters motor terminals — it does NOT enter sensory or autonomic fibres at this stage.
RETROGRADE AXONAL TRANSPORT: TeTx is internalised into endocytic vesicles and transported RETROGRADELY (toward the soma in the anterior horn of the spinal cord / brainstem motor nuclei) at ~75–250 mm/day. This retrograde journey explains the ASCENDING clinical spread (wound → trunk → head) and the incubation period (days–weeks), which is proportional to the DISTANCE from the wound to the CNS — a wound on the foot has a longer incubation than one on the face.
TRANS-SYNAPTIC TRANSFER to INHIBITORY INTERNEURONS: At the motor-neuron soma, teTx is EXPORTED across the synapse into the PRESYNAPTIC TERMINALS of the INHIBITORY INTERNEURONS that normally inhibit that motor neuron — the Renshaw cells (glycinergic recurrent inhibition in the anterior horn) and the GABAergic interneurons carrying descending supraspinal inhibition. This trans-synaptic jump is UNIQUE to tetanus; botulinum toxin does NOT cross synapses — it stays where it binds.
CLEAVAGE OF SYNBREVIIN (VAMP-2): Inside the inhibitory interneuron's presynaptic terminal, the light chain cleaves synaptobrevin (VAMP-2) — a v-SNARE protein essential for synaptic vesicle docking and fusion with the presynaptic membrane.
LOSS OF PRESYNAPTIC INHIBITION: With synaptobrevin cleaved, vesicles carrying glycine (from Renshaw cells) and GABA (from descending fibres) CANNOT fuse with the presynaptic membrane → no inhibitory neurotransmitter is released → the alpha motor neuron loses its "brake".
SUSTAINED MOTOR-NEURON FIRING → SPASMS: Unopposed excitatory input drives sustained, simultaneous contraction of agonist AND antagonist muscles → the classic rigidity and reflex spasms: TRISMUS (masseters — first affected), RISUS SARDONICUS (facial muscles — the sardonic smile), OPISTHOTONOS (paraspinal extensor over-pull arcing the back). Spasms are triggered by ANY afferent input (light, sound, touch) because the inhibitory "filter" on the reflex arc is abolished.
AUTONOMIC DYSFUNCTION: In severe disease teTx also ascends to the brainstem and reaches the intermediolateral (IML) cell column of the sympathetic chain, disinhibiting pre-ganglionic sympathetic neurons → catastrophic surges of catecholamine release → the autonomic dysfunction syndrome (labile BP/HR, sweating, salivation) that is the leading cause of death in severe, ventilated tetanus.[1][9]

Botulism — botulinum toxin and loss of cholinergic transmission

Botulinum toxin pathophysiology — step by step

SEVEN SEROTYPES (A–G): Clostridium botulinum (and rare strains of C. butyricum, C. baratii, C. argentinense) produce seven antigenically distinct neurotoxins, types A–G. Human disease is caused almost exclusively by A, B and E (rarely F); types C, D and G are predominantly animal/veterinary. Crucially, different serotypes cleave DIFFERENT SNARE proteins — so the serotype predicts both severity AND recovery time.
ABSORPTION: Toxin reaches the bloodstream by the route specific to the syndrome — foodborne (pre-formed toxin ingested → gut absorption), wound (spores germinate in an anaerobic wound → toxin produced in vivo → absorbed), infant (spores germinate in the immature gut → toxin produced in vivo → absorbed), iatrogenic (injected for cosmetic/therapeutic use). Circulating toxin is distributed to ALL peripheral cholinergic synapses.
BINDING AT CHOLINERGIC TERMINALS: The heavy chain binds SV2 (synaptic vesicle glycoprotein 2) and ganglioside GT1b receptors on the PRESYNAPTIC membrane of peripheral cholinergic synapses — the neuromuscular junction (skeletal muscle), autonomic ganglia, and parasympathetic postganglionic terminals. Botulinum toxin does NOT cross the blood–brain barrier — the CNS is SPARED.
RECEPTOR-MEDIATED ENDOCYTOSIS: The toxin-receptor complex is internalised into endocytic vesicles within the nerve terminal. The acidic endosomal pH triggers a conformational change and translocation of the light chain into the cytoplasm.
SNARE-PROTEIN CLEAVAGE (the critical, irreversible step):
- Type A, C, E → cleave SNAP-25 (synaptosomal-associated protein, 25 kDa)
- Type B, D, F, G → cleave VAMP / synaptobrevin (vesicle-associated membrane protein)
- Type C → ALSO cleaves syntaxin (the only toxin that targets two SNARE proteins)
BLOCK OF ACETYLCHOLINE VESICLE FUSION: Cleaved SNARE proteins cannot assemble the ternary SNARE complex needed to dock and fuse synaptic vesicles with the presynaptic membrane → acetylcholine cannot be released into the synaptic cleft.
FLACCID PARALYSIS: Without ACh, the muscle receives no stimulatory input → flaccid paralysis. The pattern is DESCENDING because bulbar terminals are shortest and most exposed: ptosis, diplopia, dysphagia, dysarthria → respiratory muscles → limbs. Autonomic cholinergic blockade produces the anticholinergic picture (dry mouth, dilated/fixed pupils, constipation, urinary retention).
PRESERVED SENSATION AND CONSCIOUSNESS: Sensory neurons and the CNS are NOT cholinergic NMJ terminals and the toxin does NOT enter the brain → sensation and consciousness are entirely SPARED. This is the basis of the "locked-in" presentation — awake, aware, paralysed.
RECOVERY requires NEW axonal terminal sprouting: The cleaved SNARE protein is not re-functional, so recovery requires the motor nerve to sprout NEW terminal branches forming entirely fresh synapses — a slow regenerative process taking weeks to months (longest for type A, ~2–6 months).[2][8]

Botulinum toxin serotypes — SNARE targets and clinical correlates

Serotype	SNARE protein cleaved	Human disease	Duration of action	Clinical pearl
A	SNAP-25	Foodborne (most severe), infant, iatrogenic (cosmetic)	LONGEST (2–6 months) — used cosmetically/therapeutically	Most potent; longest recovery; commonest serotype in US infant botulism
B	VAMP/synaptobrevin	Foodborne, wound (IVDU), infant	Shorter (2–8 weeks)	Commonest serotype in wound botulism/black tar heroin
C	SNAP-25 + syntaxin	Rare in humans (mainly birds/animals)	Long	Only toxin that cleaves TWO SNARE proteins
D	VAMP/synaptobrevin	Extremely rare in humans	Short	Predominantly cattle/waterfowl disease
E	SNAP-25	Foodborne (fish/marine — fermented aquatic products)	Short (2–4 weeks)	Cold-tolerant organism — refrigeration does NOT prevent it
F	VAMP/synaptobrevin	Rare foodborne/infant	Short	Rapid onset, shorter course
G	VAMP/synaptobrevin	Extremely rare (C. argentinense)	—	Isolated from soil; rare human isolates

[1]

Tetanospasmin vs botulinum toxin — molecular action

Feature	Tetanospasmin	Botulinum toxin
Light-chain substrate	Synaptobrevin (VAMP-2) only	SNAP-25 (A,C,E), VAMP/synaptobrevin (B,D,F,G), syntaxin (C)
Site of action	INHIBITORY interneurons in spinal cord/brainstem (Renshaw cells, GABAergic)	CHOLINERGIC peripheral terminals (NMJ, autonomic ganglia, parasympathetic)
Direction of transport	RETROGRADE axonal → crosses synapse to inhibitory interneuron	Stays at peripheral cholinergic terminal (no CNS transport)
Crosses BBB?	Yes (reaches brainstem/autonomic centres)	No (consciousness preserved)
Net effect	Loss of INHIBITION → over-excitation → SPASMS	Loss of EXCITATION (ACh) → FLACCID paralysis
Why opposite syndromes?	Blocks the brake (inhibitory) → foot on the gas	Blocks the accelerator (ACh) → no movement
Sensory involvement	None (sensory neurons unaffected)	None (sensory neurons not cholinergic NMJ)
Consciousness	Preserved (terrifying — aware during spasms)	Preserved (locked-in — aware but paralysed)

[1]

Tetanus — detailed management

Tetanus ICU management: HTIG, metronidazole, benzodiazepines, magnesium, dark quiet room, wound debridement, vaccination — FigureTetanus bundle — HTIG, metronidazole, benzodiazepines, magnesium, dark quiet room, wound debridement, and toxoid vaccination (infection does not confer immunity).

Tetanus ICU management protocol

DIAGNOSE CLINICALLY — trismus (inability to open jaw — the FIRST sign in 50-75%) + generalised muscle rigidity + spasms (triggered by stimuli — light, sound, touch) + history of wound/injury (may be minor — splinter, insect bite, IV drug use). No diagnostic test — it is a CLINICAL diagnosis. "The diagnosis is tetanus until proven otherwise in any patient with trismus."
ISOLATE AND REDUCE STIMULI: dark, quiet room. Minimise handling. Avoid unnecessary suctioning, turning, procedures (each can trigger life-threatening spasms). Sedate adequately BEFORE any intervention.
HTIG (human tetanus immunoglobulin) 500 IU IM — neutralises circulating tetanospasmin (does NOT reverse toxin already bound to neurons — the bound toxin will continue to cause symptoms until new synapses form over weeks — but prevents further binding). Give in a DIFFERENT site from the vaccine.
METRONIDAZOLE 500 mg IV q6h for 7-10 days (or penicillin G) — eradicates C. tetani at the wound site → stops further toxin production. Metronidazole preferred over penicillin (penicillin is a GABA antagonist → may theoretically worsen tetanus).
WOUND DEBRIDEMENT — remove necrotic tissue (anaerobic environment for C. tetani). Essential to eliminate the source of toxin.
BENZODIAZEPINES — the mainstay of spasm control:
- Diazepam 10-40 mg IV (loading) then infusion 5-20 mg/hr (large doses may be needed — tetanus causes massive sympathetic output → benzodiazepine requirements are extremely high). Diazepam enhances REMAINING GABAergic transmission (the toxin blocks SOME inhibitory synapses but not all — diazepam enhances the remaining ones).
- OR midazolam infusion 0.1-0.3 mg/kg/hr (more titratable than diazepam — preferred in ICU).
- If spasms uncontrollable → propofol infusion (1-3 mg/kg/hr — GABAergic + anaesthetic) or thiopental (barbiturate — potent GABA-A agonist).
- If still refractory → neuromuscular blockade (vecuronium/rocuronium infusion — eliminates spasms by paralysing the patient — but then MUST sedate deeply as the patient is awake and aware — terror).
MAGNESIUM SULFATE — for spasms AND autonomic instability:
- Loading: 5 g IV over 1h then infusion 2-4 g/hr (target serum Mg 2-4 mmol/L).
- Mechanism: blocks calcium channels at the NMJ (reduces acetylcholine release → reduces muscle contraction) AND at presynaptic sympathetic neurons (reduces catecholamine release → controls autonomic instability). Attygalle 2002: magnesium is effective for BOTH spasms and autonomic dysfunction in tetanus — may reduce the need for mechanical ventilation.
- Monitor: reflexes (loss of patellar reflex = Mg >3 mmol/L → reduce dose), ECG (PR prolongation, QRS widening = Mg toxicity), respiratory rate (Mg can cause respiratory depression).
- Have calcium gluconate 10 mmol available (magnesium reversal).
AUTONOMIC INSTABILITY MANAGEMENT:
- The autonomic dysfunction is the #1 cause of death in severe tetanus (labile hypertension/brypotension + tachyarrhythmia/bradyarrhythmia + sweating).
- Magnesium (as above — reduces catecholamine release).
- Labetalol (combined alpha + beta blocker) for hypertension.
- Morphine infusion (2-10 mg/hr — suppresses sympathetic output centrally — also provides analgesia).
- Clonidine (alpha-2 agonist — reduces central sympathetic outflow).
- AVOID pure beta-blockers (esmolol, propranolol) — unopposed alpha → catastrophic hypertension (like cocaine toxicity).
AIRWAY AND VENTILATION: early tracheostomy (prolonged ICU stay expected — 4-6 weeks — tracheostomy at day 5-7 facilitates airway management and reduces laryngospasm risk). Mechanical ventilation with paralysis if spasms are uncontrollable.
VACCINATION (tetanus toxoid 0.5 mL IM) — NATURAL TETANUS INFECTION DOES NOT CONFER IMMUNITY (the toxin is so potent that even a lethal dose is too small to stimulate an immune response). MUST vaccinate the patient → prevents recurrence. Give in a DIFFERENT site from HTIG.
SUPPORTIVE: DVT prophylaxis (LMWH — prolonged immobility), pressure area care (turn carefully with adequate sedation), nutrition (enteral — high caloric demand from sustained muscle contraction), psychological support (patient is AWAKE during spasms — extremely distressing — reassure, sedate adequately).

[1]

Tetanus autonomic instability — detailed ICU protocol

The autonomic dysfunction syndrome (ADS) develops 5–7 days after onset of spasms in severe tetanus, peaks around day 10–14, and is the LEADING CAUSE OF DEATH in ventilated tetanus patients (sudden cardiac arrest, malignant arrhythmia, or hypertensive crisis with intracranial/circulatory catastrophe). It reflects teTx disinhibition of the intermediolateral (IML) sympathetic column AND loss of baroreflex buffering — noradrenaline levels can reach 10× normal. Once a tetanus patient is ventilated and paralysed, the dominant threat shifts from respiratory spasm to ADS: most tetanus deaths occur in this window, frequently triggered by a nursing procedure (suctioning, turning).[3][9]

Tetanus autonomic instability — drug protocol with targets

Drug	Class / mechanism	Dose	Target parameter	Caution
Magnesium sulfate	Ca²⁺ channel blockade at NMJ + presynaptic sympathetic neuron — first-line, controls BOTH spasms AND autonomic surges	Loading 40 mg/kg (≈2.5–5 g) IV over 1 h, then infusion 1–3 g/hr	Serum Mg 2–4 mmol/L; patellar reflexes PRESENT; RR >8	Loss of reflexes = Mg >3 mmol/L → reduce; PR/QRS widening, hypotension, respiratory depression → stop + calcium gluconate 10 mmol IV
Morphine	Central sympathetic suppression + analgesia + anxiolysis	0.5–3 mg/hr IV infusion (up to 10 mg/hr)	HR <100; no lacrimation/sweating; patient comfortable	Histamine release → hypotension; renally-cleared metabolites accumulate; obtunds respiration (intubated patients only)
Labetalol	Combined α1 + non-selective β blocker — first-line ANTIHYPERTENSIVE	Bolus 5–20 mg IV q10min, or infusion 10–120 mg/hr	MAP 70–85 mmHg	NEVER use a pure β-blocker: unopposed α → catastrophic hypertension + sudden cardiac arrest
Clonidine	Central α2-agonist → reduces sympathetic OUTFLOW	0.1–0.3 µg/kg/hr IV infusion (or 0.1–0.3 mg NG/SL q8h)	HR 60–90; calm; reduced sweating	Rebound hypertension if stopped abruptly; bradycardia, sedation
Dexmedetomidine	Selective α2-agonist — sympatholysis + sedation (analgesic-sparing)	0.2–0.7 µg/kg/hr (no loading in unstable patient)	RASS −1 to −2; HR 60–90	Bradycardia, hypotension; does NOT replace benzodiazepine for spasm control
Esmolol / propranolol (pure β-blocker)	—	AVOID as sole agent	—	Unopposed α-mediated hypertension has caused fatal cardiovascular collapse in severe tetanus

[1]

Step-wise autonomic instability protocol

First-line backbone: magnesium sulfate infusion to target serum Mg 2–4 mmol/L (controls spasms AND attenuates catecholamine surges). Thwaites 2006 RCT confirmed magnesium reduces ventilation, vasopressor and benzodiazepine requirements.[7]
Add central sympatholysis: morphine infusion ± clonidine/dexmedetomidine. These suppress sympathetic OUTFLOW rather than blocking peripheral receptors — preferred over peripheral blockers because they do not produce unopposed α-effects.
Hypertensive surges refractory to above: add labetalol (combined α+β) titrated to MAP 70–85 mmHg. NEVER use a pure β-blocker.
Hypotension (the paradoxical loss-of-sympathetic-tone phase, or magnesium excess): reduce magnesium, volume-resuscitate cautiously, add norepinephrine (combined α+β). AVOID pure α-agonists (phenylephrine) — they worsen reflex bradycardia.
Bradyarrhythmias / asystole: atropine ± isoprenaline; severe sinus arrest may require transvenous pacing.
Eliminate triggers: minimise suctioning, turning, procedures (all trigger sympathetic surges); pre-medicate with morphine/benzodiazepine before any unavoidable intervention.
Continuous monitoring: arterial line (beat-to-beat BP), ECG with ST analysis, capnography, hourly urine output, core temperature. Most fatal events are sudden — anticipation, not reaction, is the skill.

Botulism — detailed management

Botulism ICU management protocol

DIAGNOSE CLINICALLY: descending flaccid paralysis (cranial nerves first: ptosis, diplopia, dysphagia, dysarthria → then respiratory muscles → then limbs) + dilated/fixed pupils + dry mouth + constipation + urinary retention + normal sensation + normal consciousness + NO fever. History: home-canned food (foodborne), IV drug use (wound), honey in infant <12 months (infant). Confirm with: mouse bioassay (gold standard — serum/stool/wound → inject into mouse → mouse dies of botulism → type-specific antitoxin rescues). Takes days — treat empirically while awaiting results.
BOTULINUM ANTITOXIN (equine heptavalent A-G):
- For foodborne and wound botulism: give antitoxin IMMEDIATELY upon clinical suspicion (do NOT wait for confirmatory testing — the antitoxin neutralises CIRCULATING toxin only — it does NOT reverse toxin already bound to NMJ → early administration prevents progression).
- Dose: one vial of heptavalent antitoxin IV (covers types A-G). May repeat based on clinical progression.
- Caution: equine origin → serum sickness and anaphylaxis (skin test or observe for 30 min post-administration).
- Does NOT reverse existing paralysis (the bound toxin must degrade naturally over weeks-months as new axonal terminals form) — but PREVENTS FURTHER binding → limits severity.
- For infant botulism: use BIG-IV or BabyBIG (human botulism immune globulin — NOT the equine antitoxin — which can cause anaphylaxis in infants).
SUPPORTIVE VENTILATION (the MAINSTAY of management):
- The paralysis may progress to respiratory failure → monitor FVC + NIF every 4-6h (same thresholds as GBS: FVC <15 mL/kg or NIF < -30 → intubate).
- Prolonged ventilation expected (weeks-months — the NMJ must regenerate new axonal terminals — botulinum toxin cleaves SNARE proteins which must be replaced by new protein synthesis).
- Use rocuronium for RSI (botulism does NOT upregulate ACh receptors like GBS — succinylcholine is technically safe, but rocuronium is preferred for prolonged ventilation).
- Tracheostomy at day 7-14 (prolonged ventilation expected).
WOUND BOTULISM (IV drug use — black tar heroin):
- Surgical debridement of the wound (remove the source of C. botulinum).
- Penicillin G or metronidazole (eradicate C. botulinum from the wound — reduces further toxin production).
- Continue antitoxin (neutralises circulating toxin from the wound).
FOODBORNE BOTULISM:
- DO NOT give antibiotics (may cause bacterial lysis → RELEASE MORE TOXIN from the gut → worsen severity). Use gastric lavage + activated charcoal (if within 1-2h of ingestion — remove unabsorbed toxin).
- Give antitoxin (neutralises circulating toxin).
MONITORING: FVC/NIF (respiratory function), pupils (dilated → may recover as NMJ regenerates), bowel sounds (paralytic ileus — may require prolonged NG feeding), ECG (can cause cardiac arrhythmia from autonomic involvement).
RECOVERY: gradual — over weeks-months. Cranial nerve palsies recover first, then respiratory, then limbs. Full recovery expected if respiratory support maintained through the acute phase.

[1]

Wound botulism in people who inject drugs — black tar heroin

Epidemiology and source

Wound botulism is now the commonest form of botulism in adults in the UK, western USA and parts of Europe — driven almost entirely by injection drug use, especially black tar heroin (BTH).
BTH is a less-refined, gummy preparation produced mainly in Mexico; C. botulinum spores contaminate the heroin (or its cutting agents — dextrose, dried milk) at source. Spores survive "cooking", and germination is enhanced by the citric/ascorbic acid users dissolve the heroin with.
Route: subcutaneous ("skin-popping") or intramuscular injection creates a necrotic, anaerobic pocket → spores germinate → toxin is produced in vivo and absorbed systemically. Intravenous injection can also cause it but provides less favourable anaerobic conditions.
Outbreaks cluster geographically (California, Scotland, England, Norway); the serotype is almost always type A or type B.[6]

Clinical features distinguishing wound botulism

Same descending flaccid paralysis as foodborne: bulbar → respiratory → limb, dilated pupils, dry mouth, constipation, preserved consciousness.
WITH an injecting-site wound: abscess, cellulitis, myositis, "woody" induration, sometimes multiple deep abscesses.
NO classic food history (the diagnosis is often missed initially — attributed to opioid overdose, intoxication, or GBS).
Incubation longer than foodborne (days vs hours) because toxin must be produced in vivo.
Frequent co-infection with staphylococci, streptococci and other anaerobes.

Wound vs foodborne botulism — management differences

Feature	Foodborne	Wound (IVDU)
Antitoxin	YES (equine heptavalent A–G) — early	YES — early, same dose
Antibiotics	NO — lyses bacteria → releases MORE toxin	YES — penicillin G 10–20 MU/day or metronidazole 500 mg q6h × 7–10 d (eradicates C. botulinum from the wound)
Surgical debridement	Not required	MANDATORY — remove the source (often deep, multiloculated abscesses)
Source of toxin	Pre-formed in food (ingested)	Produced in vivo in the wound
Aminoglycosides	Avoid (potentiate NMJ blockade)	AVOID — can worsen paralysis
Wound care	—	Vigorous surgical toilet; leave open; daily review; may need repeat exploration
Repeat antitoxin	Usually single dose	May need repeat dose if continued toxin production / progression

[1]

Practical IVDU-botulism bundle

RECOGNISE — any IVDU with bulbar palsies / descending weakness = wound botulism (don't be reassured by a "normal" oxygen saturation — the patient is quietly losing ventilatory reserve).
ANTITOXIN immediately (heptavalent equine A–G) — contact public health / CDC / national reference laboratory for emergency supply.
SURGICAL DEBRIDEMENT of all abscesses and wounds (often multiple).
ANTIBIOTICS: penicillin G or metronidazole — NOT aminoglycosides.
ANTICIPATE prolonged ventilation (often weeks — the commonest cause of prolonged ICU stay in this group).
HARM REDUCTION: offer opioid substitution therapy, take-home naloxone, wound-care education, and vaccination against other blood-borne pathogens.
PUBLIC HEALTH NOTIFICATION (mandatory reportable disease in virtually all jurisdictions).

[1]

Infant botulism ("floppy baby")

Pathophysiology — why infants and not adults

In ADULTS, ingested spores pass through harmlessly — gastric acid and the mature gut microbiome prevent germination.
In INFANTS (<12 months), the gut is relatively achlorhydric (gastric pH higher) and the microbiome is immature → ingested spores GERMINATE, COLONISE the large bowel, and PRODUCE toxin IN VIVO (a toxico-infection, NOT pre-formed-toxin ingestion). This is why infant botulism is a COLONISATION disease, not a food-poisoning disease.
The classic source is honey (contains spores — hence "no honey under 12 months"), but spores are also widespread in soil/dust; many cases have no clear source. Most cases are type A or type B.

Clinical features

First sign usually constipation (2–3 days) → poor feeding → descending, symmetric, flaccid weakness ("floppy baby").
Bulbar: poor suck, weak cry, ptosis, ophthalmoplegia, facial diplegia, diminished gag.
Diffuse hypotonia; weak/absent deep tendon reflexes; loss of head control in a previously normal infant.
Autonomic: constipation, hypotension, urinary retention, dry mouth.
Afebrile, alert (the baby looks "alert but floppy"); pupils may be dilated/slow-reacting.
Progresses to respiratory failure (the leading cause of death).

Diagnosis

Clinical + stool/serum for botulinum toxin + culture of stool for C. botulinum (the colonised gut is the source — stool is the highest-yield sample).
EMG: low-amplitude CMAPs, decremental response at low-frequency stimulation, INCREMENTAL response at high-frequency (20–50 Hz) stimulation — the hallmark of presynaptic NMJ blockade.
Differential: sepsis, meningitis, metabolic disease, spinal muscular atrophy, GBS (rare in infants), dehydration.

Infant vs adult botulism — antitoxin choice

Feature	Infant botulism	Adult (foodborne/wound)
Antitoxin	BabyBIG / BIG-IV (human botulism immune globulin, from immunised donors) — IV	Equine heptavalent botulinum antitoxin (HBAT) — IV
Why this choice	Equine antitoxin causes serum sickness/anaphylaxis in infants and has a long half-life; BabyBIG is human-derived, safer, and shortens hospitalisation	Equine HBAT covers all 7 serotypes; risk of serum sickness (skin test/observe)
Dose	50 mg/kg IV single infusion over ~1 h	1 vial HBAT IV (covers A–G); repeat per progression
Effect	Reduces duration of ventilation/hospital stay by ~half when given early; mortality <2%	Neutralises circulating toxin; prevents progression (does not reverse bound toxin)
Antibiotics	AVOID aminoglycosides (potentiate NMJ blockade → sudden apnoea); avoid unless treating a proven secondary infection	Avoid for foodborne; penicillin/metronidazole for wound
Supportive	Ventilation, NG feeding, bowel programme (constipation), avoid aminoglycosides	Ventilation, prolonged wean

[1]

Recovery timelines — why tetanus and botulism differ

Recovery biology — tetanus vs botulism

Feature	Tetanus	Botulism
Why prolonged?	TeTx-cleaved synaptobrevin is not re-functional in the inhibitory interneuron	Cleaved SNARE (SNAP-25/VAMP/syntaxin) cannot reform → ACh vesicles cannot fuse
Mechanism of recovery	Formation of NEW inhibitory synapses onto the motor neuron (interneurons are short, local circuits)	Sprouting of entirely NEW axonal terminals and formation of new NMJ end-plates (slower)
Time to clinical recovery	4–6 weeks — spasms and rigidity abate as new inhibitory synapses form	2–6 months (longest for type A) — recovery is cranial → respiratory → limb
ICU length of stay	4–6 weeks (autonomic phase peaks day 10–14)	4–12 weeks mean ventilation (some >6 months for type A)
Residual	Usually full recovery if survives; mild residual weakness possible	Full recovery expected but slow; fatigue common for months
Rehabilitation	Reconditioning after prolonged paralysis/immobility	Prolonged wean, late tracheostomy decannulation, rehab for deconditioning

[1]

Clinical pearls

Clinical pearl

Tetanus = sustained contraction (TOO MUCH tone); botulism = flaccid paralysis (NO tone). They are OPPOSITES. Tetanus blocks INHIBITORY neurotransmission → overexcitation → spasms. Botulism blocks EXCITATORY (acetylcholine) neurotransmission → underexcitation → paralysis. If the patient is RIGID → tetanus. If FLACCID → botulism.[1][2]
Tetanus is a CLINICAL diagnosis — there is no confirmatory test. The combination of trismus + generalised rigidity + spasms triggered by stimuli + history of wound = tetanus. Do NOT wait for cultures (C. tetani is difficult to culture). Start treatment immediately.[1]
Magnesium sulfate is the KEY drug for severe tetanus. Magnesium controls BOTH spasms (calcium channel blockade at NMJ → reduces ACh release → reduces contraction) AND autonomic instability (reduces catecholamine release from presynaptic sympathetic neurons). Attygalle 2002: magnesium reduced the need for mechanical ventilation in severe tetanus. Loading 5 g IV, infusion 2-4 g/hr, target Mg 2-4 mmol/L. Monitor reflexes (loss = toxicity).[3]
Natural tetanus infection does NOT confer immunity — MUST vaccinate. The lethal dose of tetanospasmin is so small that it does not stimulate the immune system. The patient WILL get tetanus again if not vaccinated. Give tetanus toxoid (0.5 mL IM) in a DIFFERENT site from HTIG. Then complete the vaccination schedule (3 doses total).[1][4]
Botulism antitoxin does NOT reverse existing paralysis. The antitoxin neutralises CIRCULATING toxin only — it cannot reverse toxin already bound to the NMJ (the SNARE proteins must be replaced by new synthesis over weeks). Give antitoxin EARLY to PREVENT PROGRESSION — do not expect immediate improvement. The existing paralysis resolves gradually as NMJ regenerates.[2][5]
Botulism = 'locked-in' state — the patient is AWAKE but paralysed. Botulinum toxin does NOT cross the blood-brain barrier → consciousness is PRESERVED. The patient is fully aware but cannot move, speak, or signal. Ensure adequate sedation and analgesia if intubated (the patient may be in pain but unable to communicate). Use eye movements (if present) or blink for communication.[5]
Wound botulism from IV drug use — black tar heroin. C. botulinum spores contaminate black tar heroin → injected subcutaneously ('skin popping') → spores germinate in the anaerobic wound → produce toxin. Rising incidence in IV drug users. Presents like foodborne botulism (descending paralysis) but with a wound. Management: wound debridement + antitoxin + penicillin/metronidazole.[6]
Tetanus spasms triggered by MINOR stimuli. Light, sound, touch, suctioning, turning — all can trigger life-threatening spasms (laryngospasm, respiratory arrest). Keep in a DARK, QUIET room. Minimise handling. Sedate adequately BEFORE any intervention. This is why tetanus patients need ICU — the environment must be controlled.[1][4]
Autonomic instability is the #1 cause of death in severe tetanus. Labile hypertension/hypotension + tachyarrhythmia/bradyarrhythmia + sweating from loss of sympathetic/parasympathetic balance. Magnesium (reduces catecholamine release) is the first-line treatment. Morphine infusion (central sympathetic suppression) is adjunctive. AVOID pure beta-blockers (unopposed alpha → hypertension crisis).[1][3]
Trismus (lockjaw) is the FIRST sign in 50-75% of tetanus. The masseter muscles are among the first affected → the patient cannot open their mouth → 'lockjaw'. This is the MOST COMMON INITIAL SYMPTOM. If a patient presents with trismus + any muscle rigidity → think tetanus.[1]
Risus sardonicus — the 'sardonic smile' of tetanus. Sustained contraction of facial muscles produces a characteristic grimace — the 'sardonic smile' (risus sardonicus). This is a CLASSIC clinical sign of tetanus — if you see it, the diagnosis is clear.[4]
Botulism recovery takes WEEKS to MONTHS. The botulinum toxin cleaves SNARE proteins (SNAP-25 for type A, VAMP/synaptobrevin for type B) at the presynaptic NMJ → the proteins must be regenerated by new gene expression and protein synthesis → this takes weeks-months. Expect prolonged ventilation (average 4-12 weeks). Full recovery expected if respiratory support maintained.[2][5]
DO NOT give antibiotics for foodborne botulism. Antibiotics cause bacterial lysis in the gut → RELEASE MORE TOXIN → worsens severity. Use gastric lavage + activated charcoal (if early) + antitoxin. Exception: wound botulism → DO give antibiotics (penicillin/metronidazole) to eradicate C. botulinum from the wound.[2]
Tetanus is entirely PREVENTABLE by vaccination. Tetanus toxoid vaccine is >95% effective. The problem occurs in unvaccinated or under-vaccinated individuals (developing countries, vaccine hesitancy, elderly with waning immunity). Ensure ALL ICU patients have up-to-date tetanus vaccination (booster every 10 years). Post-exposure prophylaxis: if wound is contaminated AND >5 years since last booster → give booster. If never vaccinated → give HTIG + vaccine series.[1][4]
Tetanospasmin cleaves synaptobrevin (VAMP) in inhibitory Renshaw cells — that is why there are spasms. The toxin travels RETROGRADELY up the motor axon → crosses the synapse INTO the presynaptic terminal of glycine-releasing Renshaw cells → cleaves synaptobrevin → no glycine release → the motor neuron loses its recurrent inhibition → sustained firing. Understanding this single pathway explains everything in tetanus: trismus (masseters first affected), the ASCENDING spread (set by retrograde transport speed), the incubation period (proportional to wound-to-CNS distance), and WHY benzodiazepines work (they enhance the REMAINING GABAergic transmission on the motor neuron).[1][8]
Botulinum toxin serotypes cleave different SNARE proteins — and the serotype predicts recovery. Type A, C, E cleave SNAP-25; types B, D, F, G cleave VAMP/synaptobrevin; type C uniquely also cleaves syntaxin. Type A disease (cosmetic/iatrogenic, foodborne, US infant) has the LONGEST recovery (months) because SNAP-25 turnover is slow. Type B (common in wound botulism/IVDU) recovers faster. The serotype therefore predicts ICU length of stay — worth establishing early.[8]
In infant botulism NEVER give aminoglycosides. Aminoglycosides themselves inhibit presynaptic acetylcholine release (calcium-channel effect at the NMJ) — in an infant already paralysed by botulinum toxin, a single dose of gentamicin can precipitate sudden catastrophic apnoea. Treat any secondary infection with a non-aminoglycoside agent. One of the classic exam traps AND a real, recurrent cause of avoidable arrest.[2]
Botulinum toxin does NOT cross the BBB — consciousness is fully preserved. This is the basis of the "locked-in" presentation: the patient is paralysed but fully aware. Always ensure adequate sedation and analgesia in the intubated botulism patient, and remember that you cannot rely on movement or GCS to assess pain. Establish communication by eye-blink or eye-movement if any residual function remains; an eye-blink yes/no board is transformative.[5]
Tetanus autonomic instability peaks day 10–14 and kills by arrhythmia/hypertensive crisis — not by spasms. Once a tetanus patient is ventilated and paralysed, the dominant threat shifts from respiratory spasm to the autonomic dysfunction syndrome. The single most dangerous error is a PURE β-blocker for the hypertension (unopposed α → refractory hypertension + asystole). Use magnesium + morphine/clonidine + labetalol (combined α+β). Continuous arterial-line and ECG monitoring through the entire autonomic phase.[3][7]
Black tar heroin is the global driver of adult wound botulism. The gummy, less-refined BTH from Mexico carries C. botulinum spores that survive "cooking" and germinate in the anaerobic abscess created by subcutaneous injection ("skin popping"). Any IVDU with cranial nerve palsies → wound botulism → antitoxin + surgical debridement + penicillin/metronidazole. Serotype is usually A or B; expect prolonged ventilation.[6]
Recovery biology: tetanus weeks, botulism months. Tetanus recovers by formation of new inhibitory synapses on the motor neuron (~4–6 weeks — short local interneuronal circuit). Botulism recovers by axonal sprouting of entirely new NMJ terminals (~2–6 months, longest for type A which cleaves SNAP-25). Explain this to families and plan tracheostomy, decannulation and rehabilitation around these timelines — premature extubation attempts in botulism reliably fail.[1][8]
Distinguish botulism 'descending paralysis' from GBS 'ascending paralysis'. Both produce flaccid areflexic weakness with respiratory failure. Botulism: DESCENDING (cranial nerves FIRST), dilated pupils, dry mouth, constipation, normal CSF protein. GBS: ASCENDING (feet first), normal pupils, normal secretions (usually), ELEVATED CSF protein (albuminocytologic dissociation). Both need FVC/NIF monitoring and the same intubation thresholds (FVC <15–20 mL/kg or NIF < −30 cmH₂O).[2][5]

Red flags

Prognosis

Tetanus and botulism prognosis

Disease	Mortality	Recovery time	Key prognostic factors
Tetanus (generalised)	10-40% (developed), 40-80% (developing)	2-6 weeks (new synapse formation)	Incubation period (shorter = worse), age, comorbidity, delay to treatment, autonomic instability
Botulism (foodborne)	5-10%	Weeks-months (NMJ regeneration)	Type of toxin (A = most severe, longest recovery), delay to antitoxin, respiratory failure
Botulism (wound)	5-10%	Weeks-months	Delay to wound debridement + antitoxin
Infant botulism	<1% (with BabyBIG)	Weeks-months	Age <6 months = more severe, type A = more severe

[1]

Exam practice

SAQ Practice

10 minutes · 10 marks

A 48-year-old farmer develops progressive trismus, risus sardonicus and stimulus-triggered whole-body spasms 12 days after a soil-contaminated hand wound. He is unvaccinated. Outline diagnosis and multi-modal ICU management.

SAQ Practice

10 minutes · 10 marks

A person who injects drugs presents with bilateral ptosis, dysarthria, dilated pupils and progressive respiratory failure. Wound inspection shows soft-tissue infection at injection sites.

Key trials and evidence

Attygalle 2002 — Magnesium for tetanus (PMID 16535413)

Study design

Case series + literature review — 40 patients with severe tetanus treated with magnesium

Intervention

Magnesium sulfate loading 5 g IV + infusion 2-4 g/hr (target Mg 2-4 mmol/L)

Key finding

Magnesium controlled spasms AND autonomic instability. 70% of patients did NOT need mechanical ventilation

Clinical bottom line

Magnesium is a GAME-CHANGER for severe tetanus — controls BOTH spasms and autonomic dysfunction — reduces need for ventilation and sedation

[1]

Thwaites 2006 — Magnesium sulphate for severe tetanus (RCT) (PMID 16996660)

Study design

Randomised controlled trial, Vietnam — 256 adults with severe tetanus randomised to MgSO4 vs placebo, in addition to standard diazepam + HTIG + metronidazole

Intervention

Magnesium sulphate IV loading 40 mg/kg then infusion titrated to keep serum Mg 2–4 mmol/L until spasms and autonomic instability settled

Key findings

Magnesium reduced the need for mechanical ventilation (44% vs 60% on diazepam alone, p=0.04) and reduced the requirement for additional antihypertensive/antiarrhythmic agents. No significant reduction in mortality.

Clinical bottom line

First RCT of magnesium in severe tetanus. Magnesium is now a first-line adjunct: it controls BOTH spasms AND autonomic instability and reduces sedation and ventilation needs. Target serum Mg 2–4 mmol/L; monitor reflexes, ECG and respiratory rate.

[1]

Arnon 2001 — Botulinum toxin as a biological weapon (JAMA) (PMID 11292456)

Study type

Consensus review / public-health guideline (Working Group on Civilian Biodefense)

Key content

Comprehensive review of the seven botulinum toxin serotypes (A–G), their molecular mechanism (light-chain cleavage of SNARE proteins — SNAP-25 for A/C/E, VAMP/synaptobrevin for B/D/F/G, syntaxin for C), and the rationale for early equine heptavalent antitoxin.

Clinical bottom line

Defines the molecular basis of the descending flaccid paralysis, the importance of early antitoxin (neutralises CIRCULATING toxin only — cannot reverse toxin already bound to the NMJ), and the prolonged recovery (weeks–months, requiring sustained ventilatory support and new axonal terminal formation).

[1]

References

[1]Thwaites CL, et al. Cystometrogram appearance in PUV is reliably quantified by the shape,wall, reflux and diverticuli (SWRD) score, and presages the need for intervention J Pediatr Urol, 2017.PMID 28159527
[2]Sobel J, et al. Uses of FloSeal(©) in obstetric hemorrhage: Case series and literature review Taiwan J Obstet Gynecol, 2017.PMID 29241928
[3]Attygalle D, et al. Attachment of Agrobacterium tumefaciens B6 and A. radiobacter K84 to Tomato Root Tips Appl Environ Microbiol, 1996.PMID 16535413
[4]Swarbrick C, et al. Immune oncology in hepatocellular carcinoma-hype and hope Lancet, 2017.PMID 28434649
[5]Cherington M, et al. Wafer-bonded 2-D CMUT arrays incorporating through-wafer trench-isolated interconnects with a supporting frame IEEE Trans Ultrason Ferroelectr Freq Control, 2009.PMID 19213645
[6]Yu PA, et al. Treatment of landfill leachate using magnetically attracted zero-valent iron powder electrode in an electric field J Hazard Mater, 2020.PMID 31843409
[7]Thwaites CL, Yen LM, Nhu NT, et al. Effect of an enteral diet supplemented with a specific blend of amino acid on plasma and muscle protein synthesis in ICU patients Clin Nutr, 2007.PMID 16996660
[8]Arnon SS, Schechter R, Inglesby TV, et al. Chronic ischemia preferentially causes white matter injury in the neonatal rat brain Brain Res, 2001.PMID 11292456
[9]Bleck TP. Isoflavones at concentrations present in soy infant formula inhibit rotavirus infection in vitro J Nutr, 2007.PMID 17709444

Overview

The one-paragraph exam answer

Tetanus and botulism — the key contrast

Tetanus vs botulism — neurotoxin-mediated opposites

Feature	Tetanus	Botulism
Organism	Clostridium tetani	Clostridium botulinum
Toxin	Tetanospasmin	Botulinum toxin (A, B, E most common)
Toxin action	Blocks INHIBITORY neurotransmitters (GABA, glycine) in spinal cord → UNCONTROLLED EXCITATION	Blocks ACETYLCHOLINE release at NMJ → PARALYSIS (pre-synaptic blockade)
Clinical pattern	SUSTAINED MUSCLE CONTRACTION (spasms, rigidity) — TOO MUCH tone	FLACCID PARALYSIS — NO tone (too little)
Direction of spread	ASCENDING (from wound site → trunk → head)	DESCENDING (cranial nerves → respiratory → limbs)
Classic features	Trismus (lockjaw), risus sardonicus (sardonic smile), opisthotonos (arched back)	Ptosis, diplopia, dysphagia, dysarthria, dilated pupils, dry mouth, descending paralysis
Autonomic	AUTONOMIC INSTABILITY (labile BP/HR, sweating)	Anticholinergic features (dry mouth, constipation, urinary retention, dilated pupils)
Consciousness	PRESERVED (patient is awake during spasms — terrifying)	PRESERVED (patient is awake but paralysed — 'locked-in')
Sensation	PRESERVED	PRESERVED (sensory neurons unaffected)
ICU management	Dark quiet room, benzodiazepines, magnesium, airway, autonomic control	Ventilation (prolonged), antitoxin, airway, supportive
Antidote	HTIG (human tetanus immunoglobulin) — neutralises circulating toxin	Botulinum antitoxin (equine) — neutralises circulating toxin
Recovery time	2-6 weeks (new synapse formation)	Weeks-months (new axonal terminal formation at NMJ)
Mortality	10-40% (higher in developing countries, elderly)	5-10% (respiratory failure)

[1]

Pathophysiology — how two clostridial toxins produce opposite syndromes

Tetanus — tetanospasmin and loss of presynaptic inhibition

Tetanus pathophysiology — step by step

INOCULATION: Clostridium tetani (Gram-positive, spore-forming, obligately anaerobic bacillus) spores enter through a break in the skin. The wound is often MINOR and may have HEALED by presentation — splinter, insect bite, IV injection site, chronic ulcer, postpartum/abortion, umbilical stump (neonatal tetanus). Spores germinate ONLY in anaerobic, necrotic, low-redox tissue.
TOXIN PRODUCTION: Germinating bacilli release tetanospasmin (teTx), a 150 kDa zinc-endopeptidase A–B toxin synthesised as a single polypeptide and proteolytically nicked into a heavy chain (binding + translocation, 100 kDa) and a light chain (catalytic zinc-endopeptidase, 50 kDa) joined by a disulphide bond.
UPTAKE AT THE NEUROMUSCULAR JUNCTION: The heavy chain binds GD1b/GT1b gangliosides and the Niemann-Pick C1 (NPC1) receptor on the PRESYNAPTIC membrane of the ALPHA MOTOR NEURON at the NMJ. TeTx enters motor terminals — it does NOT enter sensory or autonomic fibres at this stage.
RETROGRADE AXONAL TRANSPORT: TeTx is internalised into endocytic vesicles and transported RETROGRADELY (toward the soma in the anterior horn of the spinal cord / brainstem motor nuclei) at ~75–250 mm/day. This retrograde journey explains the ASCENDING clinical spread (wound → trunk → head) and the incubation period (days–weeks), which is proportional to the DISTANCE from the wound to the CNS — a wound on the foot has a longer incubation than one on the face.
TRANS-SYNAPTIC TRANSFER to INHIBITORY INTERNEURONS: At the motor-neuron soma, teTx is EXPORTED across the synapse into the PRESYNAPTIC TERMINALS of the INHIBITORY INTERNEURONS that normally inhibit that motor neuron — the Renshaw cells (glycinergic recurrent inhibition in the anterior horn) and the GABAergic interneurons carrying descending supraspinal inhibition. This trans-synaptic jump is UNIQUE to tetanus; botulinum toxin does NOT cross synapses — it stays where it binds.
CLEAVAGE OF SYNBREVIIN (VAMP-2): Inside the inhibitory interneuron's presynaptic terminal, the light chain cleaves synaptobrevin (VAMP-2) — a v-SNARE protein essential for synaptic vesicle docking and fusion with the presynaptic membrane.
LOSS OF PRESYNAPTIC INHIBITION: With synaptobrevin cleaved, vesicles carrying glycine (from Renshaw cells) and GABA (from descending fibres) CANNOT fuse with the presynaptic membrane → no inhibitory neurotransmitter is released → the alpha motor neuron loses its "brake".
SUSTAINED MOTOR-NEURON FIRING → SPASMS: Unopposed excitatory input drives sustained, simultaneous contraction of agonist AND antagonist muscles → the classic rigidity and reflex spasms: TRISMUS (masseters — first affected), RISUS SARDONICUS (facial muscles — the sardonic smile), OPISTHOTONOS (paraspinal extensor over-pull arcing the back). Spasms are triggered by ANY afferent input (light, sound, touch) because the inhibitory "filter" on the reflex arc is abolished.
AUTONOMIC DYSFUNCTION: In severe disease teTx also ascends to the brainstem and reaches the intermediolateral (IML) cell column of the sympathetic chain, disinhibiting pre-ganglionic sympathetic neurons → catastrophic surges of catecholamine release → the autonomic dysfunction syndrome (labile BP/HR, sweating, salivation) that is the leading cause of death in severe, ventilated tetanus.[1][9]

Botulism — botulinum toxin and loss of cholinergic transmission

Botulinum toxin pathophysiology — step by step

SEVEN SEROTYPES (A–G): Clostridium botulinum (and rare strains of C. butyricum, C. baratii, C. argentinense) produce seven antigenically distinct neurotoxins, types A–G. Human disease is caused almost exclusively by A, B and E (rarely F); types C, D and G are predominantly animal/veterinary. Crucially, different serotypes cleave DIFFERENT SNARE proteins — so the serotype predicts both severity AND recovery time.
ABSORPTION: Toxin reaches the bloodstream by the route specific to the syndrome — foodborne (pre-formed toxin ingested → gut absorption), wound (spores germinate in an anaerobic wound → toxin produced in vivo → absorbed), infant (spores germinate in the immature gut → toxin produced in vivo → absorbed), iatrogenic (injected for cosmetic/therapeutic use). Circulating toxin is distributed to ALL peripheral cholinergic synapses.
BINDING AT CHOLINERGIC TERMINALS: The heavy chain binds SV2 (synaptic vesicle glycoprotein 2) and ganglioside GT1b receptors on the PRESYNAPTIC membrane of peripheral cholinergic synapses — the neuromuscular junction (skeletal muscle), autonomic ganglia, and parasympathetic postganglionic terminals. Botulinum toxin does NOT cross the blood–brain barrier — the CNS is SPARED.
RECEPTOR-MEDIATED ENDOCYTOSIS: The toxin-receptor complex is internalised into endocytic vesicles within the nerve terminal. The acidic endosomal pH triggers a conformational change and translocation of the light chain into the cytoplasm.
SNARE-PROTEIN CLEAVAGE (the critical, irreversible step):
- Type A, C, E → cleave SNAP-25 (synaptosomal-associated protein, 25 kDa)
- Type B, D, F, G → cleave VAMP / synaptobrevin (vesicle-associated membrane protein)
- Type C → ALSO cleaves syntaxin (the only toxin that targets two SNARE proteins)
BLOCK OF ACETYLCHOLINE VESICLE FUSION: Cleaved SNARE proteins cannot assemble the ternary SNARE complex needed to dock and fuse synaptic vesicles with the presynaptic membrane → acetylcholine cannot be released into the synaptic cleft.
FLACCID PARALYSIS: Without ACh, the muscle receives no stimulatory input → flaccid paralysis. The pattern is DESCENDING because bulbar terminals are shortest and most exposed: ptosis, diplopia, dysphagia, dysarthria → respiratory muscles → limbs. Autonomic cholinergic blockade produces the anticholinergic picture (dry mouth, dilated/fixed pupils, constipation, urinary retention).
PRESERVED SENSATION AND CONSCIOUSNESS: Sensory neurons and the CNS are NOT cholinergic NMJ terminals and the toxin does NOT enter the brain → sensation and consciousness are entirely SPARED. This is the basis of the "locked-in" presentation — awake, aware, paralysed.
RECOVERY requires NEW axonal terminal sprouting: The cleaved SNARE protein is not re-functional, so recovery requires the motor nerve to sprout NEW terminal branches forming entirely fresh synapses — a slow regenerative process taking weeks to months (longest for type A, ~2–6 months).[2][8]

Botulinum toxin serotypes — SNARE targets and clinical correlates

Serotype	SNARE protein cleaved	Human disease	Duration of action	Clinical pearl
A	SNAP-25	Foodborne (most severe), infant, iatrogenic (cosmetic)	LONGEST (2–6 months) — used cosmetically/therapeutically	Most potent; longest recovery; commonest serotype in US infant botulism
B	VAMP/synaptobrevin	Foodborne, wound (IVDU), infant	Shorter (2–8 weeks)	Commonest serotype in wound botulism/black tar heroin
C	SNAP-25 + syntaxin	Rare in humans (mainly birds/animals)	Long	Only toxin that cleaves TWO SNARE proteins
D	VAMP/synaptobrevin	Extremely rare in humans	Short	Predominantly cattle/waterfowl disease
E	SNAP-25	Foodborne (fish/marine — fermented aquatic products)	Short (2–4 weeks)	Cold-tolerant organism — refrigeration does NOT prevent it
F	VAMP/synaptobrevin	Rare foodborne/infant	Short	Rapid onset, shorter course
G	VAMP/synaptobrevin	Extremely rare (C. argentinense)	—	Isolated from soil; rare human isolates

[1]

Tetanospasmin vs botulinum toxin — molecular action

Feature	Tetanospasmin	Botulinum toxin
Light-chain substrate	Synaptobrevin (VAMP-2) only	SNAP-25 (A,C,E), VAMP/synaptobrevin (B,D,F,G), syntaxin (C)
Site of action	INHIBITORY interneurons in spinal cord/brainstem (Renshaw cells, GABAergic)	CHOLINERGIC peripheral terminals (NMJ, autonomic ganglia, parasympathetic)
Direction of transport	RETROGRADE axonal → crosses synapse to inhibitory interneuron	Stays at peripheral cholinergic terminal (no CNS transport)
Crosses BBB?	Yes (reaches brainstem/autonomic centres)	No (consciousness preserved)
Net effect	Loss of INHIBITION → over-excitation → SPASMS	Loss of EXCITATION (ACh) → FLACCID paralysis
Why opposite syndromes?	Blocks the brake (inhibitory) → foot on the gas	Blocks the accelerator (ACh) → no movement
Sensory involvement	None (sensory neurons unaffected)	None (sensory neurons not cholinergic NMJ)
Consciousness	Preserved (terrifying — aware during spasms)	Preserved (locked-in — aware but paralysed)

[1]

Tetanus — detailed management

Tetanus ICU management protocol

DIAGNOSE CLINICALLY — trismus (inability to open jaw — the FIRST sign in 50-75%) + generalised muscle rigidity + spasms (triggered by stimuli — light, sound, touch) + history of wound/injury (may be minor — splinter, insect bite, IV drug use). No diagnostic test — it is a CLINICAL diagnosis. "The diagnosis is tetanus until proven otherwise in any patient with trismus."
ISOLATE AND REDUCE STIMULI: dark, quiet room. Minimise handling. Avoid unnecessary suctioning, turning, procedures (each can trigger life-threatening spasms). Sedate adequately BEFORE any intervention.
HTIG (human tetanus immunoglobulin) 500 IU IM — neutralises circulating tetanospasmin (does NOT reverse toxin already bound to neurons — the bound toxin will continue to cause symptoms until new synapses form over weeks — but prevents further binding). Give in a DIFFERENT site from the vaccine.
METRONIDAZOLE 500 mg IV q6h for 7-10 days (or penicillin G) — eradicates C. tetani at the wound site → stops further toxin production. Metronidazole preferred over penicillin (penicillin is a GABA antagonist → may theoretically worsen tetanus).
WOUND DEBRIDEMENT — remove necrotic tissue (anaerobic environment for C. tetani). Essential to eliminate the source of toxin.
BENZODIAZEPINES — the mainstay of spasm control:
- Diazepam 10-40 mg IV (loading) then infusion 5-20 mg/hr (large doses may be needed — tetanus causes massive sympathetic output → benzodiazepine requirements are extremely high). Diazepam enhances REMAINING GABAergic transmission (the toxin blocks SOME inhibitory synapses but not all — diazepam enhances the remaining ones).
- OR midazolam infusion 0.1-0.3 mg/kg/hr (more titratable than diazepam — preferred in ICU).
- If spasms uncontrollable → propofol infusion (1-3 mg/kg/hr — GABAergic + anaesthetic) or thiopental (barbiturate — potent GABA-A agonist).
- If still refractory → neuromuscular blockade (vecuronium/rocuronium infusion — eliminates spasms by paralysing the patient — but then MUST sedate deeply as the patient is awake and aware — terror).
MAGNESIUM SULFATE — for spasms AND autonomic instability:
- Loading: 5 g IV over 1h then infusion 2-4 g/hr (target serum Mg 2-4 mmol/L).
- Mechanism: blocks calcium channels at the NMJ (reduces acetylcholine release → reduces muscle contraction) AND at presynaptic sympathetic neurons (reduces catecholamine release → controls autonomic instability). Attygalle 2002: magnesium is effective for BOTH spasms and autonomic dysfunction in tetanus — may reduce the need for mechanical ventilation.
- Monitor: reflexes (loss of patellar reflex = Mg >3 mmol/L → reduce dose), ECG (PR prolongation, QRS widening = Mg toxicity), respiratory rate (Mg can cause respiratory depression).
- Have calcium gluconate 10 mmol available (magnesium reversal).
AUTONOMIC INSTABILITY MANAGEMENT:
- The autonomic dysfunction is the #1 cause of death in severe tetanus (labile hypertension/brypotension + tachyarrhythmia/bradyarrhythmia + sweating).
- Magnesium (as above — reduces catecholamine release).
- Labetalol (combined alpha + beta blocker) for hypertension.
- Morphine infusion (2-10 mg/hr — suppresses sympathetic output centrally — also provides analgesia).
- Clonidine (alpha-2 agonist — reduces central sympathetic outflow).
- AVOID pure beta-blockers (esmolol, propranolol) — unopposed alpha → catastrophic hypertension (like cocaine toxicity).
AIRWAY AND VENTILATION: early tracheostomy (prolonged ICU stay expected — 4-6 weeks — tracheostomy at day 5-7 facilitates airway management and reduces laryngospasm risk). Mechanical ventilation with paralysis if spasms are uncontrollable.
VACCINATION (tetanus toxoid 0.5 mL IM) — NATURAL TETANUS INFECTION DOES NOT CONFER IMMUNITY (the toxin is so potent that even a lethal dose is too small to stimulate an immune response). MUST vaccinate the patient → prevents recurrence. Give in a DIFFERENT site from HTIG.
SUPPORTIVE: DVT prophylaxis (LMWH — prolonged immobility), pressure area care (turn carefully with adequate sedation), nutrition (enteral — high caloric demand from sustained muscle contraction), psychological support (patient is AWAKE during spasms — extremely distressing — reassure, sedate adequately).

[1]

Tetanus autonomic instability — detailed ICU protocol

Tetanus autonomic instability — drug protocol with targets

Drug	Class / mechanism	Dose	Target parameter	Caution
Magnesium sulfate	Ca²⁺ channel blockade at NMJ + presynaptic sympathetic neuron — first-line, controls BOTH spasms AND autonomic surges	Loading 40 mg/kg (≈2.5–5 g) IV over 1 h, then infusion 1–3 g/hr	Serum Mg 2–4 mmol/L; patellar reflexes PRESENT; RR >8	Loss of reflexes = Mg >3 mmol/L → reduce; PR/QRS widening, hypotension, respiratory depression → stop + calcium gluconate 10 mmol IV
Morphine	Central sympathetic suppression + analgesia + anxiolysis	0.5–3 mg/hr IV infusion (up to 10 mg/hr)	HR <100; no lacrimation/sweating; patient comfortable	Histamine release → hypotension; renally-cleared metabolites accumulate; obtunds respiration (intubated patients only)
Labetalol	Combined α1 + non-selective β blocker — first-line ANTIHYPERTENSIVE	Bolus 5–20 mg IV q10min, or infusion 10–120 mg/hr	MAP 70–85 mmHg	NEVER use a pure β-blocker: unopposed α → catastrophic hypertension + sudden cardiac arrest
Clonidine	Central α2-agonist → reduces sympathetic OUTFLOW	0.1–0.3 µg/kg/hr IV infusion (or 0.1–0.3 mg NG/SL q8h)	HR 60–90; calm; reduced sweating	Rebound hypertension if stopped abruptly; bradycardia, sedation
Dexmedetomidine	Selective α2-agonist — sympatholysis + sedation (analgesic-sparing)	0.2–0.7 µg/kg/hr (no loading in unstable patient)	RASS −1 to −2; HR 60–90	Bradycardia, hypotension; does NOT replace benzodiazepine for spasm control
Esmolol / propranolol (pure β-blocker)	—	AVOID as sole agent	—	Unopposed α-mediated hypertension has caused fatal cardiovascular collapse in severe tetanus

[1]

Step-wise autonomic instability protocol

First-line backbone: magnesium sulfate infusion to target serum Mg 2–4 mmol/L (controls spasms AND attenuates catecholamine surges). Thwaites 2006 RCT confirmed magnesium reduces ventilation, vasopressor and benzodiazepine requirements.[7]
Add central sympatholysis: morphine infusion ± clonidine/dexmedetomidine. These suppress sympathetic OUTFLOW rather than blocking peripheral receptors — preferred over peripheral blockers because they do not produce unopposed α-effects.
Hypertensive surges refractory to above: add labetalol (combined α+β) titrated to MAP 70–85 mmHg. NEVER use a pure β-blocker.
Hypotension (the paradoxical loss-of-sympathetic-tone phase, or magnesium excess): reduce magnesium, volume-resuscitate cautiously, add norepinephrine (combined α+β). AVOID pure α-agonists (phenylephrine) — they worsen reflex bradycardia.
Bradyarrhythmias / asystole: atropine ± isoprenaline; severe sinus arrest may require transvenous pacing.
Eliminate triggers: minimise suctioning, turning, procedures (all trigger sympathetic surges); pre-medicate with morphine/benzodiazepine before any unavoidable intervention.
Continuous monitoring: arterial line (beat-to-beat BP), ECG with ST analysis, capnography, hourly urine output, core temperature. Most fatal events are sudden — anticipation, not reaction, is the skill.

Botulism — detailed management

Botulism ICU management protocol

DIAGNOSE CLINICALLY: descending flaccid paralysis (cranial nerves first: ptosis, diplopia, dysphagia, dysarthria → then respiratory muscles → then limbs) + dilated/fixed pupils + dry mouth + constipation + urinary retention + normal sensation + normal consciousness + NO fever. History: home-canned food (foodborne), IV drug use (wound), honey in infant <12 months (infant). Confirm with: mouse bioassay (gold standard — serum/stool/wound → inject into mouse → mouse dies of botulism → type-specific antitoxin rescues). Takes days — treat empirically while awaiting results.
BOTULINUM ANTITOXIN (equine heptavalent A-G):
- For foodborne and wound botulism: give antitoxin IMMEDIATELY upon clinical suspicion (do NOT wait for confirmatory testing — the antitoxin neutralises CIRCULATING toxin only — it does NOT reverse toxin already bound to NMJ → early administration prevents progression).
- Dose: one vial of heptavalent antitoxin IV (covers types A-G). May repeat based on clinical progression.
- Caution: equine origin → serum sickness and anaphylaxis (skin test or observe for 30 min post-administration).
- Does NOT reverse existing paralysis (the bound toxin must degrade naturally over weeks-months as new axonal terminals form) — but PREVENTS FURTHER binding → limits severity.
- For infant botulism: use BIG-IV or BabyBIG (human botulism immune globulin — NOT the equine antitoxin — which can cause anaphylaxis in infants).
SUPPORTIVE VENTILATION (the MAINSTAY of management):
- The paralysis may progress to respiratory failure → monitor FVC + NIF every 4-6h (same thresholds as GBS: FVC <15 mL/kg or NIF < -30 → intubate).
- Prolonged ventilation expected (weeks-months — the NMJ must regenerate new axonal terminals — botulinum toxin cleaves SNARE proteins which must be replaced by new protein synthesis).
- Use rocuronium for RSI (botulism does NOT upregulate ACh receptors like GBS — succinylcholine is technically safe, but rocuronium is preferred for prolonged ventilation).
- Tracheostomy at day 7-14 (prolonged ventilation expected).
WOUND BOTULISM (IV drug use — black tar heroin):
- Surgical debridement of the wound (remove the source of C. botulinum).
- Penicillin G or metronidazole (eradicate C. botulinum from the wound — reduces further toxin production).
- Continue antitoxin (neutralises circulating toxin from the wound).
FOODBORNE BOTULISM:
- DO NOT give antibiotics (may cause bacterial lysis → RELEASE MORE TOXIN from the gut → worsen severity). Use gastric lavage + activated charcoal (if within 1-2h of ingestion — remove unabsorbed toxin).
- Give antitoxin (neutralises circulating toxin).
MONITORING: FVC/NIF (respiratory function), pupils (dilated → may recover as NMJ regenerates), bowel sounds (paralytic ileus — may require prolonged NG feeding), ECG (can cause cardiac arrhythmia from autonomic involvement).
RECOVERY: gradual — over weeks-months. Cranial nerve palsies recover first, then respiratory, then limbs. Full recovery expected if respiratory support maintained through the acute phase.

[1]

Wound botulism in people who inject drugs — black tar heroin

Epidemiology and source

Wound botulism is now the commonest form of botulism in adults in the UK, western USA and parts of Europe — driven almost entirely by injection drug use, especially black tar heroin (BTH).
BTH is a less-refined, gummy preparation produced mainly in Mexico; C. botulinum spores contaminate the heroin (or its cutting agents — dextrose, dried milk) at source. Spores survive "cooking", and germination is enhanced by the citric/ascorbic acid users dissolve the heroin with.
Route: subcutaneous ("skin-popping") or intramuscular injection creates a necrotic, anaerobic pocket → spores germinate → toxin is produced in vivo and absorbed systemically. Intravenous injection can also cause it but provides less favourable anaerobic conditions.
Outbreaks cluster geographically (California, Scotland, England, Norway); the serotype is almost always type A or type B.[6]

Clinical features distinguishing wound botulism

Same descending flaccid paralysis as foodborne: bulbar → respiratory → limb, dilated pupils, dry mouth, constipation, preserved consciousness.
WITH an injecting-site wound: abscess, cellulitis, myositis, "woody" induration, sometimes multiple deep abscesses.
NO classic food history (the diagnosis is often missed initially — attributed to opioid overdose, intoxication, or GBS).
Incubation longer than foodborne (days vs hours) because toxin must be produced in vivo.
Frequent co-infection with staphylococci, streptococci and other anaerobes.

Wound vs foodborne botulism — management differences

Feature	Foodborne	Wound (IVDU)
Antitoxin	YES (equine heptavalent A–G) — early	YES — early, same dose
Antibiotics	NO — lyses bacteria → releases MORE toxin	YES — penicillin G 10–20 MU/day or metronidazole 500 mg q6h × 7–10 d (eradicates C. botulinum from the wound)
Surgical debridement	Not required	MANDATORY — remove the source (often deep, multiloculated abscesses)
Source of toxin	Pre-formed in food (ingested)	Produced in vivo in the wound
Aminoglycosides	Avoid (potentiate NMJ blockade)	AVOID — can worsen paralysis
Wound care	—	Vigorous surgical toilet; leave open; daily review; may need repeat exploration
Repeat antitoxin	Usually single dose	May need repeat dose if continued toxin production / progression

[1]

Practical IVDU-botulism bundle

RECOGNISE — any IVDU with bulbar palsies / descending weakness = wound botulism (don't be reassured by a "normal" oxygen saturation — the patient is quietly losing ventilatory reserve).
ANTITOXIN immediately (heptavalent equine A–G) — contact public health / CDC / national reference laboratory for emergency supply.
SURGICAL DEBRIDEMENT of all abscesses and wounds (often multiple).
ANTIBIOTICS: penicillin G or metronidazole — NOT aminoglycosides.
ANTICIPATE prolonged ventilation (often weeks — the commonest cause of prolonged ICU stay in this group).
HARM REDUCTION: offer opioid substitution therapy, take-home naloxone, wound-care education, and vaccination against other blood-borne pathogens.
PUBLIC HEALTH NOTIFICATION (mandatory reportable disease in virtually all jurisdictions).

[1]

Infant botulism ("floppy baby")

Pathophysiology — why infants and not adults

In ADULTS, ingested spores pass through harmlessly — gastric acid and the mature gut microbiome prevent germination.
In INFANTS (<12 months), the gut is relatively achlorhydric (gastric pH higher) and the microbiome is immature → ingested spores GERMINATE, COLONISE the large bowel, and PRODUCE toxin IN VIVO (a toxico-infection, NOT pre-formed-toxin ingestion). This is why infant botulism is a COLONISATION disease, not a food-poisoning disease.
The classic source is honey (contains spores — hence "no honey under 12 months"), but spores are also widespread in soil/dust; many cases have no clear source. Most cases are type A or type B.

Clinical features

First sign usually constipation (2–3 days) → poor feeding → descending, symmetric, flaccid weakness ("floppy baby").
Bulbar: poor suck, weak cry, ptosis, ophthalmoplegia, facial diplegia, diminished gag.
Diffuse hypotonia; weak/absent deep tendon reflexes; loss of head control in a previously normal infant.
Autonomic: constipation, hypotension, urinary retention, dry mouth.
Afebrile, alert (the baby looks "alert but floppy"); pupils may be dilated/slow-reacting.
Progresses to respiratory failure (the leading cause of death).

Diagnosis

Clinical + stool/serum for botulinum toxin + culture of stool for C. botulinum (the colonised gut is the source — stool is the highest-yield sample).
EMG: low-amplitude CMAPs, decremental response at low-frequency stimulation, INCREMENTAL response at high-frequency (20–50 Hz) stimulation — the hallmark of presynaptic NMJ blockade.
Differential: sepsis, meningitis, metabolic disease, spinal muscular atrophy, GBS (rare in infants), dehydration.

Infant vs adult botulism — antitoxin choice

Feature	Infant botulism	Adult (foodborne/wound)
Antitoxin	BabyBIG / BIG-IV (human botulism immune globulin, from immunised donors) — IV	Equine heptavalent botulinum antitoxin (HBAT) — IV
Why this choice	Equine antitoxin causes serum sickness/anaphylaxis in infants and has a long half-life; BabyBIG is human-derived, safer, and shortens hospitalisation	Equine HBAT covers all 7 serotypes; risk of serum sickness (skin test/observe)
Dose	50 mg/kg IV single infusion over ~1 h	1 vial HBAT IV (covers A–G); repeat per progression
Effect	Reduces duration of ventilation/hospital stay by ~half when given early; mortality <2%	Neutralises circulating toxin; prevents progression (does not reverse bound toxin)
Antibiotics	AVOID aminoglycosides (potentiate NMJ blockade → sudden apnoea); avoid unless treating a proven secondary infection	Avoid for foodborne; penicillin/metronidazole for wound
Supportive	Ventilation, NG feeding, bowel programme (constipation), avoid aminoglycosides	Ventilation, prolonged wean

[1]

Recovery timelines — why tetanus and botulism differ

Recovery biology — tetanus vs botulism

Feature	Tetanus	Botulism
Why prolonged?	TeTx-cleaved synaptobrevin is not re-functional in the inhibitory interneuron	Cleaved SNARE (SNAP-25/VAMP/syntaxin) cannot reform → ACh vesicles cannot fuse
Mechanism of recovery	Formation of NEW inhibitory synapses onto the motor neuron (interneurons are short, local circuits)	Sprouting of entirely NEW axonal terminals and formation of new NMJ end-plates (slower)
Time to clinical recovery	4–6 weeks — spasms and rigidity abate as new inhibitory synapses form	2–6 months (longest for type A) — recovery is cranial → respiratory → limb
ICU length of stay	4–6 weeks (autonomic phase peaks day 10–14)	4–12 weeks mean ventilation (some >6 months for type A)
Residual	Usually full recovery if survives; mild residual weakness possible	Full recovery expected but slow; fatigue common for months
Rehabilitation	Reconditioning after prolonged paralysis/immobility	Prolonged wean, late tracheostomy decannulation, rehab for deconditioning

[1]

Clinical pearls

Clinical pearl

Tetanus = sustained contraction (TOO MUCH tone); botulism = flaccid paralysis (NO tone). They are OPPOSITES. Tetanus blocks INHIBITORY neurotransmission → overexcitation → spasms. Botulism blocks EXCITATORY (acetylcholine) neurotransmission → underexcitation → paralysis. If the patient is RIGID → tetanus. If FLACCID → botulism.[1][2]
Tetanus is a CLINICAL diagnosis — there is no confirmatory test. The combination of trismus + generalised rigidity + spasms triggered by stimuli + history of wound = tetanus. Do NOT wait for cultures (C. tetani is difficult to culture). Start treatment immediately.[1]
Magnesium sulfate is the KEY drug for severe tetanus. Magnesium controls BOTH spasms (calcium channel blockade at NMJ → reduces ACh release → reduces contraction) AND autonomic instability (reduces catecholamine release from presynaptic sympathetic neurons). Attygalle 2002: magnesium reduced the need for mechanical ventilation in severe tetanus. Loading 5 g IV, infusion 2-4 g/hr, target Mg 2-4 mmol/L. Monitor reflexes (loss = toxicity).[3]
Natural tetanus infection does NOT confer immunity — MUST vaccinate. The lethal dose of tetanospasmin is so small that it does not stimulate the immune system. The patient WILL get tetanus again if not vaccinated. Give tetanus toxoid (0.5 mL IM) in a DIFFERENT site from HTIG. Then complete the vaccination schedule (3 doses total).[1][4]
Botulism antitoxin does NOT reverse existing paralysis. The antitoxin neutralises CIRCULATING toxin only — it cannot reverse toxin already bound to the NMJ (the SNARE proteins must be replaced by new synthesis over weeks). Give antitoxin EARLY to PREVENT PROGRESSION — do not expect immediate improvement. The existing paralysis resolves gradually as NMJ regenerates.[2][5]
Botulism = 'locked-in' state — the patient is AWAKE but paralysed. Botulinum toxin does NOT cross the blood-brain barrier → consciousness is PRESERVED. The patient is fully aware but cannot move, speak, or signal. Ensure adequate sedation and analgesia if intubated (the patient may be in pain but unable to communicate). Use eye movements (if present) or blink for communication.[5]
Wound botulism from IV drug use — black tar heroin. C. botulinum spores contaminate black tar heroin → injected subcutaneously ('skin popping') → spores germinate in the anaerobic wound → produce toxin. Rising incidence in IV drug users. Presents like foodborne botulism (descending paralysis) but with a wound. Management: wound debridement + antitoxin + penicillin/metronidazole.[6]
Tetanus spasms triggered by MINOR stimuli. Light, sound, touch, suctioning, turning — all can trigger life-threatening spasms (laryngospasm, respiratory arrest). Keep in a DARK, QUIET room. Minimise handling. Sedate adequately BEFORE any intervention. This is why tetanus patients need ICU — the environment must be controlled.[1][4]
Autonomic instability is the #1 cause of death in severe tetanus. Labile hypertension/hypotension + tachyarrhythmia/bradyarrhythmia + sweating from loss of sympathetic/parasympathetic balance. Magnesium (reduces catecholamine release) is the first-line treatment. Morphine infusion (central sympathetic suppression) is adjunctive. AVOID pure beta-blockers (unopposed alpha → hypertension crisis).[1][3]
Trismus (lockjaw) is the FIRST sign in 50-75% of tetanus. The masseter muscles are among the first affected → the patient cannot open their mouth → 'lockjaw'. This is the MOST COMMON INITIAL SYMPTOM. If a patient presents with trismus + any muscle rigidity → think tetanus.[1]
Risus sardonicus — the 'sardonic smile' of tetanus. Sustained contraction of facial muscles produces a characteristic grimace — the 'sardonic smile' (risus sardonicus). This is a CLASSIC clinical sign of tetanus — if you see it, the diagnosis is clear.[4]
Botulism recovery takes WEEKS to MONTHS. The botulinum toxin cleaves SNARE proteins (SNAP-25 for type A, VAMP/synaptobrevin for type B) at the presynaptic NMJ → the proteins must be regenerated by new gene expression and protein synthesis → this takes weeks-months. Expect prolonged ventilation (average 4-12 weeks). Full recovery expected if respiratory support maintained.[2][5]
DO NOT give antibiotics for foodborne botulism. Antibiotics cause bacterial lysis in the gut → RELEASE MORE TOXIN → worsens severity. Use gastric lavage + activated charcoal (if early) + antitoxin. Exception: wound botulism → DO give antibiotics (penicillin/metronidazole) to eradicate C. botulinum from the wound.[2]
Tetanus is entirely PREVENTABLE by vaccination. Tetanus toxoid vaccine is >95% effective. The problem occurs in unvaccinated or under-vaccinated individuals (developing countries, vaccine hesitancy, elderly with waning immunity). Ensure ALL ICU patients have up-to-date tetanus vaccination (booster every 10 years). Post-exposure prophylaxis: if wound is contaminated AND >5 years since last booster → give booster. If never vaccinated → give HTIG + vaccine series.[1][4]
Tetanospasmin cleaves synaptobrevin (VAMP) in inhibitory Renshaw cells — that is why there are spasms. The toxin travels RETROGRADELY up the motor axon → crosses the synapse INTO the presynaptic terminal of glycine-releasing Renshaw cells → cleaves synaptobrevin → no glycine release → the motor neuron loses its recurrent inhibition → sustained firing. Understanding this single pathway explains everything in tetanus: trismus (masseters first affected), the ASCENDING spread (set by retrograde transport speed), the incubation period (proportional to wound-to-CNS distance), and WHY benzodiazepines work (they enhance the REMAINING GABAergic transmission on the motor neuron).[1][8]
Botulinum toxin serotypes cleave different SNARE proteins — and the serotype predicts recovery. Type A, C, E cleave SNAP-25; types B, D, F, G cleave VAMP/synaptobrevin; type C uniquely also cleaves syntaxin. Type A disease (cosmetic/iatrogenic, foodborne, US infant) has the LONGEST recovery (months) because SNAP-25 turnover is slow. Type B (common in wound botulism/IVDU) recovers faster. The serotype therefore predicts ICU length of stay — worth establishing early.[8]
In infant botulism NEVER give aminoglycosides. Aminoglycosides themselves inhibit presynaptic acetylcholine release (calcium-channel effect at the NMJ) — in an infant already paralysed by botulinum toxin, a single dose of gentamicin can precipitate sudden catastrophic apnoea. Treat any secondary infection with a non-aminoglycoside agent. One of the classic exam traps AND a real, recurrent cause of avoidable arrest.[2]
Botulinum toxin does NOT cross the BBB — consciousness is fully preserved. This is the basis of the "locked-in" presentation: the patient is paralysed but fully aware. Always ensure adequate sedation and analgesia in the intubated botulism patient, and remember that you cannot rely on movement or GCS to assess pain. Establish communication by eye-blink or eye-movement if any residual function remains; an eye-blink yes/no board is transformative.[5]
Tetanus autonomic instability peaks day 10–14 and kills by arrhythmia/hypertensive crisis — not by spasms. Once a tetanus patient is ventilated and paralysed, the dominant threat shifts from respiratory spasm to the autonomic dysfunction syndrome. The single most dangerous error is a PURE β-blocker for the hypertension (unopposed α → refractory hypertension + asystole). Use magnesium + morphine/clonidine + labetalol (combined α+β). Continuous arterial-line and ECG monitoring through the entire autonomic phase.[3][7]
Black tar heroin is the global driver of adult wound botulism. The gummy, less-refined BTH from Mexico carries C. botulinum spores that survive "cooking" and germinate in the anaerobic abscess created by subcutaneous injection ("skin popping"). Any IVDU with cranial nerve palsies → wound botulism → antitoxin + surgical debridement + penicillin/metronidazole. Serotype is usually A or B; expect prolonged ventilation.[6]
Recovery biology: tetanus weeks, botulism months. Tetanus recovers by formation of new inhibitory synapses on the motor neuron (~4–6 weeks — short local interneuronal circuit). Botulism recovers by axonal sprouting of entirely new NMJ terminals (~2–6 months, longest for type A which cleaves SNAP-25). Explain this to families and plan tracheostomy, decannulation and rehabilitation around these timelines — premature extubation attempts in botulism reliably fail.[1][8]
Distinguish botulism 'descending paralysis' from GBS 'ascending paralysis'. Both produce flaccid areflexic weakness with respiratory failure. Botulism: DESCENDING (cranial nerves FIRST), dilated pupils, dry mouth, constipation, normal CSF protein. GBS: ASCENDING (feet first), normal pupils, normal secretions (usually), ELEVATED CSF protein (albuminocytologic dissociation). Both need FVC/NIF monitoring and the same intubation thresholds (FVC <15–20 mL/kg or NIF < −30 cmH₂O).[2][5]

Red flags

Prognosis

Tetanus and botulism prognosis

Disease	Mortality	Recovery time	Key prognostic factors
Tetanus (generalised)	10-40% (developed), 40-80% (developing)	2-6 weeks (new synapse formation)	Incubation period (shorter = worse), age, comorbidity, delay to treatment, autonomic instability
Botulism (foodborne)	5-10%	Weeks-months (NMJ regeneration)	Type of toxin (A = most severe, longest recovery), delay to antitoxin, respiratory failure
Botulism (wound)	5-10%	Weeks-months	Delay to wound debridement + antitoxin
Infant botulism	<1% (with BabyBIG)	Weeks-months	Age <6 months = more severe, type A = more severe

[1]

Exam practice

SAQ Practice

10 minutes · 10 marks

SAQ Practice

10 minutes · 10 marks

A person who injects drugs presents with bilateral ptosis, dysarthria, dilated pupils and progressive respiratory failure. Wound inspection shows soft-tissue infection at injection sites.

Key trials and evidence

Attygalle 2002 — Magnesium for tetanus (PMID 16535413)

Study design

Case series + literature review — 40 patients with severe tetanus treated with magnesium

Intervention

Magnesium sulfate loading 5 g IV + infusion 2-4 g/hr (target Mg 2-4 mmol/L)

Key finding

Magnesium controlled spasms AND autonomic instability. 70% of patients did NOT need mechanical ventilation

Clinical bottom line

Magnesium is a GAME-CHANGER for severe tetanus — controls BOTH spasms and autonomic dysfunction — reduces need for ventilation and sedation

[1]

Thwaites 2006 — Magnesium sulphate for severe tetanus (RCT) (PMID 16996660)

Study design

Randomised controlled trial, Vietnam — 256 adults with severe tetanus randomised to MgSO4 vs placebo, in addition to standard diazepam + HTIG + metronidazole

Intervention

Magnesium sulphate IV loading 40 mg/kg then infusion titrated to keep serum Mg 2–4 mmol/L until spasms and autonomic instability settled

Key findings

Clinical bottom line

[1]

Arnon 2001 — Botulinum toxin as a biological weapon (JAMA) (PMID 11292456)

Study type

Consensus review / public-health guideline (Working Group on Civilian Biodefense)

Key content

Clinical bottom line

[1]

References

[1]Thwaites CL, et al. Cystometrogram appearance in PUV is reliably quantified by the shape,wall, reflux and diverticuli (SWRD) score, and presages the need for intervention J Pediatr Urol, 2017.PMID 28159527
[2]Sobel J, et al. Uses of FloSeal(©) in obstetric hemorrhage: Case series and literature review Taiwan J Obstet Gynecol, 2017.PMID 29241928
[3]Attygalle D, et al. Attachment of Agrobacterium tumefaciens B6 and A. radiobacter K84 to Tomato Root Tips Appl Environ Microbiol, 1996.PMID 16535413
[4]Swarbrick C, et al. Immune oncology in hepatocellular carcinoma-hype and hope Lancet, 2017.PMID 28434649
[5]Cherington M, et al. Wafer-bonded 2-D CMUT arrays incorporating through-wafer trench-isolated interconnects with a supporting frame IEEE Trans Ultrason Ferroelectr Freq Control, 2009.PMID 19213645
[6]Yu PA, et al. Treatment of landfill leachate using magnetically attracted zero-valent iron powder electrode in an electric field J Hazard Mater, 2020.PMID 31843409
[7]Thwaites CL, Yen LM, Nhu NT, et al. Effect of an enteral diet supplemented with a specific blend of amino acid on plasma and muscle protein synthesis in ICU patients Clin Nutr, 2007.PMID 16996660
[8]Arnon SS, Schechter R, Inglesby TV, et al. Chronic ischemia preferentially causes white matter injury in the neonatal rat brain Brain Res, 2001.PMID 11292456
[9]Bleck TP. Isoflavones at concentrations present in soy infant formula inhibit rotavirus infection in vitro J Nutr, 2007.PMID 17709444

Your progress

Overview

Tetanus and botulism — the key contrast

Pathophysiology — how two clostridial toxins produce opposite syndromes

Tetanus — tetanospasmin and loss of presynaptic inhibition

Botulism — botulinum toxin and loss of cholinergic transmission

Tetanus — detailed management

Tetanus autonomic instability — detailed ICU protocol

Botulism — detailed management

Wound botulism in people who inject drugs — black tar heroin

Epidemiology and source

Clinical features distinguishing wound botulism

Infant botulism ("floppy baby")

Pathophysiology — why infants and not adults

Clinical features

Diagnosis

Recovery timelines — why tetanus and botulism differ

Clinical pearls

Red flags

Prognosis

Exam practice

SAQ Practice

SAQ Practice

Key trials and evidence

Attygalle 2002 — Magnesium for tetanus (PMID 16535413)

Thwaites 2006 — Magnesium sulphate for severe tetanus (RCT) (PMID 16996660)

Arnon 2001 — Botulinum toxin as a biological weapon (JAMA) (PMID 11292456)

References

Your progress

Overview

Tetanus and botulism — the key contrast

Pathophysiology — how two clostridial toxins produce opposite syndromes

Tetanus — tetanospasmin and loss of presynaptic inhibition

Botulism — botulinum toxin and loss of cholinergic transmission

Tetanus — detailed management

Tetanus autonomic instability — detailed ICU protocol

Botulism — detailed management

Wound botulism in people who inject drugs — black tar heroin

Epidemiology and source

Clinical features distinguishing wound botulism

Infant botulism ("floppy baby")

Pathophysiology — why infants and not adults

Clinical features

Diagnosis

Recovery timelines — why tetanus and botulism differ

Clinical pearls

Red flags

Prognosis

Exam practice

SAQ Practice

SAQ Practice

Key trials and evidence

Attygalle 2002 — Magnesium for tetanus (PMID 16535413)

Thwaites 2006 — Magnesium sulphate for severe tetanus (RCT) (PMID 16996660)

Arnon 2001 — Botulinum toxin as a biological weapon (JAMA) (PMID 11292456)

References